Hepatic Disease in HIV-Infected Patients
Summary
- Fixed-dose emtricitabine/tenofovir DF and emtricitabine/tenofovir alafenamide are currently included as NRTI backbones for almost all recommended first-line antiretroviral regimens, according to the DHHS guidelines on ART (Management Guidelines)[DHHS ART]
- Antiretroviral therapy regimens containing emtricitabine/tenofovir DF or emtricitabine/tenofovir alafenamide are also endorsed by the DHHS as appropriate treatments for HBV coinfection, as these agents are active against HBV as well as HIV[DHHS ART]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content